Novo Nordisk(US:NVO) Yahoo Finance·2025-12-19 19:53Core Insights - Novo Nordisk A/S has received a positive opinion from the European Medicines Agency for a higher dosage of Wegovy, indicating strong potential for weight loss treatment [1][2] - The clinical trial results show an average weight loss of approximately 20.7% at 72 weeks for individuals without diabetes, with one in three participants achieving a weight loss of 25% or more [2] - The company is also pursuing regulatory approval for a single-dose device to deliver Wegovy 7.2 mg in Europe, with additional reviews ongoing in the US and UK [3] Market Outlook - Wall Street analysts have a mixed outlook on Novo Nordisk A/S, with HSBC maintaining a Hold rating and raising the price target from $47 to $54, while Argus Research downgraded the stock from Buy to Hold without a price target [4] - The company is recognized as a leading player in the global healthcare market, particularly in diabetes and obesity care [4]